Physicians
resolvemdx-RGB-logo-for dark

Resolve your patient’s UTI with accurate diagnosis and personalized antimicrobial options.

How Resolve mdx works

Resolve mdx combines the precision of PCR pathogen identification and resistance gene detection with proprietary susceptibility testing for personalized antimicrobial solutions to address your patient’s specific infection. 

Resolve mdx uses PCR to identify the uropathogens and resistance genes
Proprietary susceptibility testing provides antimicrobial options for your patient’s unique infection
Fast Turnaround Time

Direct treatment sooner. Results delivered within 24-48 hours vs 3-5 days with urine culture. 

High sensitivity

Using the precision of PCR, Resolve mdx detects 19 of the most common bacterial and fungal uropathogens and 9 resistance genes. 

Polymicrobial Infections
Screen Shot 2022-08-25 at 5.15.01 PM
Identifies specific organisms and antimicrobial options in polymicrobial infections, which occur in up to 52% of UTIs.1 No “mixed flora” results. 
ASTX™ Susceptibility Testing
Screen Shot 2022-08-25 at 5.17.52 PM

ASTX™ tests all detected pathogens in the sample simultaneously to identify antimicrobials that work against the whole infection. 

Field Effect: Polymicrobial Solutions

In polymicrobial samples, pathogens may demonstrate different antimicrobial susceptibilities, creating a “field effect” in the culture. In these cases, a single oral antimicrobial solution will not be effective against the infection. Resolve mdx uses ASTX™ to detect the subpopulation of resistant bacteria in the sample and identifies oral antimicrobials to address each pathogen. 

Actionable Report

Resolve mdx facilitates diagnostic decision making with an actionable and easy to understand report with the information needed to make informed treatment decisions. 

  • Organisms identified 
  • Resistance genes detected 
  • Whole urine susceptibility results 
  • Prioritized oral antimicrobial options 

Antibiotic Stewardship

A recent study found that nearly 50% of UTI patients received the wrong antibiotic.2 By identifying patient-specific treatment options, Resolve mdx promotes appropriate use of antibiotics, reducing reliance on empiric therapy.  Resolve mdx tests uropathogens against a panel of 26 antibiotics. Except in rare cases, Resolve mdx provides at least one (1) oral antimicrobial option to resolve each patient’s infection. 
Edit Content
  1. Brooks MA, Thomas L, Magi-Galluzzi C, et al. Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urol Oncol. 2022;40(3):104.e1-104.e7.
  2. Mehralivand S, Shih JH, Harmon S, et al. A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology. 2019;290(3):709-719.
  3. Brooks MA, Thomas L, Magi-Galluzzi C, et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precis Oncol. 2021;5:PO.20.00325.
  4. Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-gene genomic prostate score test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. Urology. 2020;143:103-111.
  5. Data on file.
  6. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550-560.
  7. Cullen J, Rosner IL, Brand TC, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68(1):123-131.
  8. Van Den Eeden SK, Lu R, Zhang N, et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2018;73(1):129-138.
  9. Eggener S, Karsh LI, Richardson T, et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76-82.
  10. Lin DW, Zheng Y, McKenney JK, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol. 2020;38(14):1549-1557.
  11. Badani KK, Kemeter MJ, Febbo PG, et al. The impact of a biopsy based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. Urol Pract. 2015;2(4), 181-189.
  12. Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX® prostate cancer assay in clinical practice for treatment selection in men newly diagnosed with prostate cancer: a retrospective chart review analysis. Urol Pract. 2015; 2(6), 343-348.
  13. Albala D, Kemeter MJ, Febbo PG, et al. Health economic impact and prospective clinical utility of Oncotype DX® Genomic Prostate Score. Rev Urol. 2016;18(3):123-132.
  14. Eure G, Germany R, Given R, et al. Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort. Urology. 2017;107:67-75.
  15. Lynch JA, Rothney MP, Salup RR, et al. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay. Am J Manag Care. 2018;24(1 Suppl):S4-S10.
  16. Leapman MS, Westphalen AC, Ameli N, et al. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One. 2017;12(10):e0185535.
  17. Kornberg Z, Cowan JE, Westphalen AC, et al. Genomic Prostate Score, PI-RADS™ version 2 and progression in men with prostate cancer on active surveillance. J Urol. 2019;201(2):300-307.
  18. Salmasi A, Said J, Shindel AW, et al. A 17-gene genomic prostate score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance imaging fusion targeted and systematic prostate biopsy. J Urol. 2018;200(3):564-572.
  19. Magi-Galluzzi C, Isharwal S, Falzarano SM, et al. The 17-gene genomic prostate score assay predicts outcome after radical prostatectomy independent of PTEN status. Urology. 2018;121:132-138.
  20. Cullen J, Lynch JA, Klein EA, et al. Multicenter comparison of 17-gene genomic prostate score as a predictor of outcomes in African American and Caucasian American men with clinically localized prostate cancer. J Urol. 2021;205(4):1047-1054.
  21. Murphy AB, Carbunaru S, Nettey OS, et al. A 17-gene panel genomic prostate score has similar predictive accuracy for adverse pathology at radical prostatectomy in African American and European American men. Urology. 2020;142:166-173.
  22. Covas Moschovas M, Chew C, Bhat S, et al. Association between Oncotype DX genomic prostate score and adverse tumor pathology after radical prostatectomy. Eur Urol Focus. 2021;S2405-4569(21)00094-8.
  23. Aboushwareb T, Bennett J, Yuan Y, et al. Active surveillance or watchful waiting in clinically low-risk prostate cancer patients in the SEER database with and without an Oncotype Dx genomic prostate score assay. J Urol.2021;206(3S):e1094 (MP62-06).
  24. Brand TC, Zhang N, Crager MR, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score Urology. 2016;89:69-75.

How To Order Resolve mdx

Ordering Resolve mdx for Urinary Tract Infection is simple and easy. 

MDX.TestKitPackaging.Resolve

Report Access

Secure mdx is a safe and secure HIPAA compliant tool that gives you access to patient reports online.